Cited by

• Prevalence and clinical implications of germline mutations among Jordanian patients with ovarian cancer. The Jordanian exploratory cancer genetics (Jo-ECAG) ovarian study.

  Abdel-Razeq H, Al-Azzam K, Elemian S, Abu-Fares H, Abu Sheikha A, Bani Hani H, Bater R, Sharaf B, Heald B, Esplin ED, Nielsen SM, Alkyam M, Abujamous L, Al-Attary A. Abdel-Razeq H, et al. Mol Genet Genomic Med. 2023 Apr;11(4):e2125. doi: 10.1002/mgg3.2125. Epub 2022 Dec 19. Mol Genet Genomic Med. 2023. PMID: 36537080 Free PMC article.
• The Feasibility of Implementing Mainstream Germline Genetic Testing in Routine Cancer Care-A Systematic Review.

  Bokkers K, Vlaming M, Engelhardt EG, Zweemer RP, van Oort IM, Kiemeney LALM, Bleiker EMA, Ausems MGEM. Bokkers K, et al. Cancers (Basel). 2022 Feb 19;14(4):1059. doi: 10.3390/cancers14041059. Cancers (Basel). 2022. PMID: 35205807 Free PMC article. Review.
• Germline variant screening with targeted next generation sequencing in prostate cancer: phenotype-genotype correlation.

  Çakır AY, Hekimler Öztürk K, Özorak A. Çakır AY, et al. Turk J Med Sci. 2022 Feb;52(1):131-143. doi: 10.3906/sag-2105-348. Epub 2022 Feb 22. Turk J Med Sci. 2022. PMID: 34579513 Free PMC article.
• Germline multigene panel testing revealed a BRCA2 pathogenic variant in a patient with suspected Lynch syndrome.

  Yoshihama T, Hirasawa A, Sugano K, Yoshida T, Ushiama M, Ueki A, Akahane T, Nanki Y, Sakai K, Makabe T, Yamagami W, Susumu N, Kameyama K, Kosaki K, Aoki D. Yoshihama T, et al. Int Cancer Conf J. 2020 Oct 9;10(1):6-10. doi: 10.1007/s13691-020-00449-9. eCollection 2021 Jan. Int Cancer Conf J. 2020. PMID: 33489693 Free PMC article.
• Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer.

  Ryu JS, Lee HY, Cho EH, Yoon KA, Kim MK, Joo J, Lee ES, Kang HS, Lee S, Lee DO, Lim MC, Kong SY. Ryu JS, et al. Cancer Sci. 2020 Oct;111(10):3912-3925. doi: 10.1111/cas.14600. Epub 2020 Sep 2. Cancer Sci. 2020. PMID: 32761968 Free PMC article.